MedTrace Logo

Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome

NCT00821574 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2017-03-01

No results posted yet for this study

Summary

This study will evaluate the efficacy of a multi factorial preventive scheme of action (including fluvastatin and valsartan) to reduce the overall risk level in patients with metabolic syndrome.

Conditions

  • Hypertension, Dyslypidaemia

Interventions

DRUG

Fluvastatin

Fluvastatin: daily 80 mg, oral

DRUG

Valsartan

Valsartan: daily 160 mg, oral

DRUG

Hydrochlorothiazide

Hydrochlorothiazide: daily 12.5mg, oral

Sponsors & Collaborators

Principal Investigators

  • Alessandro Rossi, MD · ASL Terni 4, Narni (TR) - Italy

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Primary Completion
2007-03-31
Completion
2007-03-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00821574 on ClinicalTrials.gov